Welcome to This Week in Infectious Disease. This week we're covering 8 notable papers spanning advances in HIV prevention and management, antimicrobial stewardship in common outpatient infections, and the global landscape of surveillance, new drugs, and prevention. Let's dive in.

This week's papers:

1. Global and regional molecular epidemiology of HIV-1 during 1990-2024: systematic review, global survey, and analysis of prevalence. — The Lancet. Infectious diseases 2026
2. Azithromycin for Preschoolers with Wheezing in the Emergency Department. — The New England journal of medicine 2026
3. Multi-Center Real-World Implementation Outcomes of Lenacapavir for HIV Pre-Exposure Prophylaxis. — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026
4. Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists. — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026
5. Quantifying relative health impact across Gavi, the Vaccine Alliance's portfolio in 117 countries at the subregional level: a modelling study. — Lancet (London, England) 2026
6. Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial. — Lancet (London, England) 2026
7. Amoxicillin-Clavulanate vs Amoxicillin for Acute Sinusitis in Adults. — JAMA 2026
8. Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies. — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026

Listen at AudioScholar